Financials in USD. Standardized financial statements.
A compact view of how CelLBxHealth plc turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.86M | $2.19M | $1.04M | $1.01M | $762,000 | $871,500 | $678,000 | $628,000 | $498,000 | $361,000 |
| Revenue Growth? | +30.9% | +110.0% | +2.8% | +32.9% | -12.6% | +28.5% | +8.0% | +26.1% | +38.0% | 0.0% |
| Cost of Revenue? | $1.08M | $2.59M | $428,000 | $302,000 | $165,000 | $1.55M | $155,000 | $169,000 | $123,000 | $107,000 |
| Gross Profit? | $1.78M | -$408,000 | $613,000 | $711,000 | $597,000 | -$678,000 | $523,000 | $459,000 | $375,000 | $254,000 |
| Gross Margin? | +62.2% | -18.7% | +58.9% | +70.2% | +78.3% | -77.8% | +77.1% | +73.1% | +75.3% | +70.4% |
| Operating Expenses? | $16.88M | $21.35M | $24.82M | $17.95M | $14.33M | $12.46M | $11.42M | $9.39M | $7.81M | $5.70M |
| Operating Income? | -$15.10M | -$21.76M | -$24.21M | -$17.23M | -$13.73M | -$13.14M | -$10.90M | -$8.93M | -$7.43M | -$5.45M |
| EBITDA? | -$13.02M | -$19.00M | -$24.39M | -$15.72M | -$12.23M | -$11.29M | -$9.82M | -$8.13M | -$6.90M | -$5.04M |
| Income Before Tax | -$15.03M | -$21.63M | -$24.44M | -$17.36M | -$13.74M | -$13.56M | -$10.87M | -$8.93M | -$7.41M | -$5.43M |
| Income Tax Expense | -$804,000 | -$1.50M | -$2.75M | -$2.35M | -$2.14M | -$2.22M | -$1.94M | -$1.39M | -$1.02M | -$309,000 |
| Net Income? | -$14.22M | -$20.13M | -$21.69M | -$15.01M | -$11.61M | -$11.33M | -$8.94M | -$7.56M | -$6.57M | -$4.89M |
| EPS? | $-0.48 | $-0.77 | $-0.88 | $-0.67 | $-0.65 | $-0.69 | $-0.66 | $-0.79 | $-0.89 | $-0.83 |
| Diluted EPS? | $-0.48 | $-0.77 | $-0.88 | $-0.67 | $-0.65 | $-0.69 | $-0.66 | $-0.79 | $-0.89 | $-0.83 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality